Platinum retreatment of platinum-resistant ovarian cancer after nonplatinum therapy

Gynecologic Oncology

Volumn 91, Issue 1, 2003, Pages 123-129

  Leitao Jr , Mario M ^a   Hummer, Amanda ^a   Dizon, Don S ^a   Aghajanian, Carol ^a   Hensley, Martee ^b   Sabbatini, Paul ^a   Venkatraman, Ennapadam ^a   Spriggs, David R ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CA 125 ANTIGEN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; NAVELBINE; PACLITAXEL; PLATINUM DERIVATIVE; TOPOTECAN;

ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG HYPERSENSITIVITY; DRUG RESPONSE; FEMALE; HUMAN; OVARY CANCER; PREDICTION; PRIORITY JOURNAL; PROVOCATION TEST; RETREATMENT; RETROSPECTIVE STUDY; TREATMENT FAILURE;

EID: 0141645587     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-8258(03)00464-5     Document Type: Article

References (28)

1. McGuire W.P., Ozols R.F. Chemotherapy of advanced ovarian cancer. Semin Oncol. 25:1998;340-348.
2. McGuire W.P., Hoskins W.J., Brady M.F., Brady M.F., Kucera P.R., Partridge E.E., et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 334:1996;1-6.
3. Piccart M.J., Bertelsen K., James K., Cassidy J., Mangioni C., Simonsen E., et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer three-year results . J Natl Cancer Inst. 92:2000;699-708.
4. Cannistra S.A. Is there a "best" choice of second-line agent in the treatment of recurrent, potentially platinum-sensitive ovarian cancer? J Clin Oncol. 20:2002;1158-1160. [editorial].
5. Markman M., Rothman R., Hakes T., Reichman B., Hoskins W., Rubin S., et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol. 9:1991;389-393.
6. Bookman M.A. Extending the platinum-free interval in recurrent ovarian cancer the role of topotecan in second-line therapy . Oncologist. 4:1999;87-94.
7. Eisenhauer EA, Vermoken JB, van Glabbeke. Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients. Ann Oncol 1997;8:963-968.
8. Markman M., Hoskins W. Responses to salvage chemotherapy in ovarian cancer a critical need for precise definitions of the treated population . J Clin Oncol. 10:1992;513-514. [editorial].
9. Bookman M.A., Malmstrom H., Bolis G., Gordon A., Lissoni A., Krebs J.B., et al. Topotecan for the treatment of advanced epithelial ovarian cancer an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel . J Clin Oncol. 16:1998;3345-3352.
10. Gordon A.N., Granai C.O., Rose P.G., Hainsworth J., Lopez A., Weissman C., et al. Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer. J Clin Oncol. 18:2000;3093-3100.
11. Markman M., Kennedy A., Webster K., Peterson G., Kulp B., Belinson J. Phase 2 trial of liposomal doxorubicin (40 mg/m2) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum. Gynecol Oncol. 78:2000;369-372.
12. Rose P.G., Blessing J.A., Mayer A.R., Homesley H.D. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma a gynecologic oncology group study . J Clin Oncol. 16:1998;405-410.
13. Bajetta E., Di Leo A., Biganzoli L., Mariani L., Cappuzzo F., Di Bartolomeo M., et al. Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer activity in platinum-resistant disease . J Clin Oncol. 14:1996;2546-2551.
14. Francis P., Schneider J., Hann L., Balmaceda C., Barakat R., Phillips M., et al. Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer. J Clin Oncol. 12:1994;2301-2308.
15. Markman M., Hakes T., Reichman B., Lewis J.L. Jr, Rubin S., Jones W., et al. Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer activity in platinum-resistant disease . J Clin Oncol. 10:1992;243-248.
16. Markman M., Kennedy A., Sutton G., Hurteau J., Webster K., Peterson G., et al. Phase 2 trial of single agent ifosfamide/mesna in patients with platinum/paclitaxel refractory ovarian cancer who have not previously been treated with an alkylating agent. Gynecol Oncol. 70:1998;272-274.
17. Zanotti K.M., Belinson J.L., Kennedy A.W., Webster K.D., Markman M. Treatment of relapsed carcinoma of the ovary with single-agent paclitaxel following exposure to paclitaxel and platinum employed as initial therapy. Gynecol Oncol. 79:2000;211-215.
18. Shapiro J.D., Millward M.J., Rischin D., Michael M., Walcher V., Francis P.A., et al. Activity of gemcitabine in patients with advanced ovarian cancer responses seen following platinum and paclitaxel . Gynecol Oncol. 63:1996;89-93.
19. Gordon A.N., Fleagle J.T., Guthrie D., Parkin D.E., Gore M.E., Lacave A.J. Recurrent epithelial ovarian carcinoma a randomized phase III study of pegylated liposomal doxorubicin versus topotecan . J Clin Oncol. 19:2001;3312-3322.
20. Bolis G., Scarfone G., Giardina G., Villa A., Mangili G., Melpignano M., et al. Carboplatin alone vs carboplatin plus epidoxorubicin as second-line therapy for cisplatin- or carboplatin-sensitive ovarian cancer. Gynecol Oncol. 81:2001;3-9.
21. Kavanagh J., Tresukosol D., Edwards C., Freedman R., Gonzalez de Leon C., Fishman A., et al. Carboplatin reinduction after taxane in patients with platinum-refractory epithelial ovarian cancer. J Clin Oncol. 13:1995;1584-1588.
22. Rose P.G., Mossbruger K., Fusco N., Smrekar M., Eaton S., Rodriguez M. Gemcitabine reverses cisplatin resistance demonstration of activity in platinum- and multidrug-resistant ovarian and peritoneal carcinoma . Gynecol Oncol. 88:2003;17-21.
23. Rustin G.J.S., Marples M., Nelstrop A.E., Mahmoudi M., Meyer T. Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels. J Clin Oncol. 19:2001;4054-4057.
24. Dizon D.S., Sabbatini P.J., Aghajanian C., Hensley M.L., Spriggs D.R. Analysis of patients with epithelial ovarian cancer or fallopian tube carcinoma retreated with cisplatin after the development of a carboplatin allergy. Gynecol Oncol. 84:2002;378-382.
25. Thigpen J.T., Blessing J.A., Ball H., Hummel S.J., Barrett R.J. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy a Gynecologic Oncology Group study . J Clin Oncol. 12:1994;1748-1753.
26. Gore M.E., Fryatt I., Wiltshaw E., Dawson T. Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol Oncol. 36:1990;207-211.
27. van der Burg M.E.L., de Wit R., van Putten W.L.J., Logmans A., Kruit W.H.J., Stoter G., et al. Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancer. Br J Cancer. 86:2002;19-25.
28. Markman M. "Recurrence within 6 months of platinum therapy:" an adequate definition of "platinum-refractory" ovarian cancer? Gynecol Oncol. 69:1998;91-92. [editorial].